The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy
Giant cell arteritis (GCA) characterized by the paradoxical discrepancy between the high effectiveness of glucocorticoid (GCs) in the short term and the increase in signs associated with the persistence of inflammatory activity and the accumulation of organ damage induced by GCs in the long term, wh...
Saved in:
| Main Authors: | E. L. Nasonov, T. V. Beketova, A. M. Satybaldyev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2024-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01) -
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01) -
International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results
by: T. V. Beketova, et al.
Published: (2016-10-01) -
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01) -
Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01)